Akebia Therapeutics Sets Ambitious 2026 Pipeline Expansion Goals Amid $1 Billion Dialysis Market Expectations

jueves, 26 de febrero de 2026, 11:33 am ET1 min de lectura
AKBA--

Akebia Therapeutics reported total net product revenue of $227 million for 2025, with commercial launch of Vafseo. CEO John Butler emphasized 2025 as an important year for the company. Management expects expansion of pipeline to 2026, with data catalysts in the $1 billion dialysis market.

Comentarios



Add a public comment...
Sin comentarios

Aún no hay comentarios